Phase 3 Trials Begin on Non-Invasive Bladder Cancer Treatment
Last month Spectrum Pharmaceuticals (NASDAQ: SPPI) announced it initiated Phase 3 registrational trials on the company’s new proprietary drug treatment for non-invasive bladder cancer. The drug, named EOquin (R), becomes activated by reductase enzymes found in cancer cells and is formulated for administration directly into the urinary bladder.
The American Cancer Society estimates that there are more than 400,000 bladder cancer patients in the U.S. and more than one million cases in Europe at any given time. Non-invasive bladder cancer accounts for 75 to 80 percent of all bladder cancer cases at first diagnosis and is characterized by a high recurrence rate. No new drugs have been marketed in the last 20 years to combat the disease.
More information about the trial criteria can be obtained at www.clinicaltrials.gov
Source: Spectrum Pharmaceuticals
Bladder Illustration: PLWC
Related Audio: TTMed Interview of Dr. Soloway
Print This
|
|
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URI
Leave a comment
Browse All Categories: Next article: Northern Leopard Frog is Looking Like a Prince to Bath’s Brain Cancer Researchers
Previous article: New York-Presbyterian Hospital Provides Webcasts on Colorectal Cancer Treatment Methods
